Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HER-1 vaccine - Center of Molecular Immunology

Next Previous
Drug Profile

HER-1 vaccine - Center of Molecular Immunology

Alternative Names: HER-1-ECD-VSSP; HER1-ECD; HER1-VSSP vaccine

Latest Information Update: 31 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center of Molecular Immunology
  • Class Cancer vaccines
  • Mechanism of Action Epidermal growth factor receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cancer
  • No development reported Prostate cancer

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for phase-I development in Prostate-cancer(Hormone refractory) in Cuba (IM, Injection)
  • 26 Dec 2017 Center of Molecular Immunology plans a phase I trial for Prostate cancer (Hormone refractory), Squamous cell carcinoma of the head and neck (Late-stage disease, Metastatic disease) and Colon cancer in Cuba (SC) in November 2017 (RPCEC00000258)
  • 16 Dec 2016 Phase-I development is ongoing in Prostate cancer in Cuba
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top